^
Association details:
| Biomarker: | EGFR overexpression + HER-2 overexpression |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | buparlisib (AN2025) (PI3K inhibitor) + varlitinib (ASLAN001) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines
Excerpt:
Elevated expressions of EGFR and HER2 were observed in KKU-214 and KKU-100 cells and varlitinib can suppress CCA cell growth in the micromolar range...While KKU-100 cells showed a poor response to varlitinib, a combination of varlitinib with BKM-120 improved anti-tumor activity.
DOI:
https://dx.doi.org/10.2147%2FDDDT.S250061
